Pfizer, acquisition of Anacor Pharmaceuticals for more than $ 5 billion

9 years ago - Published in Finance, Fundamental Analysis

Pfizer buys Anacor Pharmaceuticals in a transaction valued $ 5.2 billion. The two companies have signed the agreement and it is stated in a joint statement that the transaction is in cash and that Pfizer will pay $ 99.25 for each Anacor action.

The price represents a premium of 55% over Friday Anacor title last Friday. The transaction, which is expected to close in the third quarter of 2016, should not impact on the guidance of this year, said Pfizer. Meanwhile springs forward the title Anacor: the Wall Street pre-market marks an increase of over 53 percent.

In April, the mega merger between Pfizer and Irish Allergan had jumped after the move by the US Treasury against tax inversion, the practice among corporate mergers aimed only to make the displacement of the legal office in countries with favorable tax treatment.